Vialwirebiotech, curated
October 1, 2026, 9:52 AM
August 18, 2026
- 9:00 AM · BioWorld9:00 AMFDA approves Amygdala Neurosciences’ IND for ANS-858 — BioWorld
- 9:00 AM · BioWorld9:00 AMNIH SBIR grant supports Taxis’ FtsZ inhibitors for <em>C. difficile</em> — BioWorld
- 9:00 AM · BioWorld9:00 AMEvaxion discloses EVX-05 therapeutic glioblastoma vaccine — BioWorld
- 9:00 AM · BioWorld9:00 AMChugai grants GSK license for anti-dengue antibody AID-351 — BioWorld
- 8:59 AM · Drug Discovery World8:59 AMNucleai and Gilead Sciences enter oncology ADC collaboration — Drug Discovery World
- 8:00 AM · BioWorld8:00 AMLupin approval; Ocumension NDA — BioWorld
- 8:00 AM · BioWorld8:00 AMCrystalo dermatology deal; Beone collaboration — BioWorld
- 7:01 AM · STAT News7:01 AMSTAT+: Amylyx endocrine drug succeeds in pivotal study — STAT News
- 6:36 AM · PharmaVoice6:36 AMHow Helus’ new CEO plans to scale its psychedelic drug pipeline — PharmaVoice
- 6:29 AM · Pharmaceutical Technology6:29 AMUpdated UK guidance for finerenone introduces new treatment for HF patients — Pharmaceutical Technology
- 6:02 AM · Pharmaceutical Technology6:02 AMLEO outlays $435m for rights to Tanabe’s rare disease drug for sun-induced pain — Pharmaceutical Technology
- 6:00 AM · STAT News
- 5:09 AM · Pharmaceutical Technology5:09 AMFaeth’s PIKTOR plus paclitaxel combo gains FDA fast track status — Pharmaceutical Technology
- 3:56 AM · Pharmaceutical Technology3:56 AMFulcrum and Slate Medicines sign merger agreement — Pharmaceutical Technology
- 12:00 AM · FT — Pharmaceuticals12:00 AMBig pharma warns Germany’s attempts to curb drug prices will backfire — FT — Pharmaceuticals
August 17, 2026
- 3:23 PM · STAT News
- 12:00 PM · BioWorld12:00 PMArgenx’s Vyvgart hits phase III endpoint in myositis subtype — BioWorld
- 12:00 PM · BioWorld12:00 PMCourt clears path for suit claiming BMS delayed drug approval — BioWorld
- 12:00 PM · BioWorld12:00 PMJanssen quits CD20/CD19 CAR T development; Abelzeta regains rights — BioWorld
- 12:00 PM · BioWorld12:00 PMBoan’s CD228 ADC shows early activity in solid tumors — BioWorld
- 12:00 PM · BioWorld12:00 PMFirst Duravyu AMD phase III inserts doubt for Eyepoint’s second — BioWorld
- 12:00 PM · BioWorld12:00 PMRyan Cohlhepp takes Bicara helm; Ying Huang to lead K2 Tx — BioWorld
- 12:00 PM · BioWorld12:00 PMRedx to join Nasdaq via Skye merger; raises $125M privately — BioWorld
- 11:13 AM · BioPharma Dive11:13 AMAstraZeneca scraps Phase 3 trial of new bispecific in lung cancer — BioPharma Dive
- 9:11 AM · BioPharma Dive9:11 AMFDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMTissue analysis from Nurexone’s Exopten spinal cord injury study — BioWorld
- 9:00 AM · BioWorld9:00 AMGrants support Fannin’s RapDC therapy for Ewing sarcoma — BioWorld
- 7:58 AM · SCMP — Tech7:58 AMChinese team aims to put ‘smart’ diabetes probiotic on US shelves within 2 years — SCMP — Tech
- 6:47 AM · Pharmaceutical Technology6:47 AMSandoz targets industry patent void with $322m Henlius deal — Pharmaceutical Technology
- 6:47 AM · Pharmaceutical Technology6:47 AMLantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval — Pharmaceutical Technology
- 6:19 AM · Drug Discovery World6:19 AMTrial will assess precision therapeutic vaccine in oesophageal cancer — Drug Discovery World
- 6:00 AM · Drug Discovery World6:00 AMFirst patient receives novel heavy-chain-only antibody — Drug Discovery World
- 6:00 AM · SCMP — Tech
- 5:20 AM · Pharmaceutical Technology5:20 AMEMA validates Pfizer and Valneva’s Lyme disease vaccine — Pharmaceutical Technology
- 4:42 AM · Pharmaceutical Technology4:42 AMFDA grants fast track status to Phanes’ spevatamig for advanced BTC — Pharmaceutical Technology
- 4:00 AM · Drug Discovery World4:00 AMImmunotherapy for Parkinson’s gets FDA Fast Track Designation — Drug Discovery World
August 16, 2026
- 11:15 PM · Science (News)11:15 PMNIH plan to keep peer-review scores for grants secret draws concern — Science (News)